Text Size

Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Hospital Clinic of Barcelona.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT00878852
First received: April 8, 2009
Last updated: May 20, 2009
Last verified: May 2009
History of Changes
  Purpose

Cannabis use among Spanish adolescents has been increasing in the last decade. It has been related to poor school achievement, delinquency, substance use and psychiatric disorders. Furthermore, psychoactive substance use in adolescents presenting psychiatric disorders can result in the development of substance use disorders or the worsening of psychopathology. Thus, there's an urge to develop efficient interventions in the treatment of these disorders. Therapeutic approaches based on cognitive-behavioural therapy and motivational interviewing have demonstrated a limited efficacy in this population. Programs based on contingency management have been reported to be useful both in adult and adolescents, too. But it still remains unclear whether a combination of these therapeutic approaches is feasible and brings a better cost-benefit relation.

The investigators' project aims to evaluate the added benefits of supplementing a standard intervention on cannabis use, based on combined approach that includes motivational and cognitive-behavioural elements, with a contingency management program. Therefore, pre and post-treatment evaluation will be carried forward in a sample of 30 adolescents (aged 12-18) that initiate treatment for cannabis use related disorder at the Child and Adolescent Psychiatry Department of the Hospital Clinic in Barcelona. Participants will be randomly assigned to a standard treatment group or an experimental group in which standard treatment will be supplemented with a contingency management protocol. As a secondary objective, a prospective assessment of neuropsychological performance related to cannabis use or abstinence will be carried forward.


Condition Intervention
Marijuana Abuse
 Behavioral: Standard treatment
Behavioral: Standard Treatment Plus Contingency Management Program

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of a Contingency Management Program in the Treatment of Adolescents With Cannabis Use Disorders in a Child and Adolescent Psychiatry and Psychology Department

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Percentage of marijuana active users [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of negative urine-screens [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of completed intervention sessions [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Scores in psychopathology and drug scales (T-ASI, SDQ, BDI, Cannabis Problem Questionnaire) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: April 2009
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard treatment
Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
 Behavioral: Standard treatment
Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
Experimental: Experimental
Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
 Behavioral: Standard Treatment Plus Contingency Management Program
Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.

  Eligibility

Ages Eligible for Study:   12 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence of DSM-IV-TR criteria of cannabis abuse and/or dependence
  • Signed informed consent

Exclusion Criteria:

  • Mental retardation
  • Presence of a substance use disorder other than nicotine or cannabis
  • Severe or unstable medical
  • Presence at the moment of inclusion of severe acute psychopathology (acute psychotic symptoms, severe depressive symptoms, suicidal ideation)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00878852

Contacts
Contact: Javier Goti, M.D 0034932279970 jgoti@clinic.ub.es

Locations
Spain
Hospital Clinic Barcelona Recruiting
Barcelona, Spain, 08015
Sponsors and Collaborators
Hospital Clinic of Barcelona
Investigators
Principal Investigator: Javier Goti, M.D Hospital Clinic Barcelona
  More Information

Publications:

Responsible Party: Javier Goti, Hospital Clinic Barcelona
ClinicalTrials.gov Identifier: NCT00878852     History of Changes
Other Study ID Numbers: PI08/90331, 4363/2008 (Ethics Comitee HCP)
Study First Received: April 8, 2009
Last Updated: May 20, 2009
Health Authority: Spain: Ministry of Health and Consumption

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 19, 2013